CS
JANX icon

Candriam SCA’s Janux Therapeutics JANX Stock Holding History

Candriam SCA’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-137,105
Closed -$6.23M – 691
2024
Q3 		$6.23M Buy
137,105
+25,101
+22% +$1.09M 0.04% 326
2024
Q2 		$4.69M Buy
112,004
+31,999
+40% +$1.5M 0.03% 348
2024
Q1 		$3.01M Buy
+80,005
New +$1.74M 0.02% 436

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Candriam SCA's JANX Position: Q4 2024 in Review

Candriam SCA sold out of Janux Therapeutics (JANX) in Q4 2024, closing a stake of 137,105 shares — an estimated $6.23M sold.

Candriam SCA first reported a position in JANX in Q1 2024 and held it in 3 quarters. The position peaked at $6.23M in Q3 2024. 216 funds tracked by Wall St. Rank hold JANX as of Q4 2024.

  • Candriam SCA reported no remaining Janux Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Candriam SCA sold 137,105 Janux Therapeutics shares in Q4 2024, an estimated $6.23M.
  • Candriam SCA first reported a position in Janux Therapeutics in Q1 2024 and held it in 3 quarters.
  • Candriam SCA's Janux Therapeutics position peaked at $6.23M in Q3 2024.
  • 216 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2024.

Based on Candriam SCA's 13F filing for Q4 2024, filed 7 Feb 2025.